Our
News
Check back on a regualr basis
for futher updates.
VasoDynamics strengthens the Board with key appointments
VasoDynamics strengthens the Board with key appointments Building a strong Board of industry experts to enable progress to market acces • Dr Laurence Reilly, Non-executive Chair
NG11-2 Phase-Ib Study Completes Last Patient Visit
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer
NG11-2 Phase-Ib Study Closes Enrolment – Results Expected Autumn 2024
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer.
VasoDynamics Presents Phase-1b NG11-2 Clinical Data at ESTRO Conference
At the recent ESTRO conference in Glasgow on 3-7 May 2024, VasoDynamics presented the preliminary findings from its Phase-1b Study with NG11-2.
VasoDynamics Receives Global Health & Pharma Biotechnology 2024 Award
VasoDynamics receives Global Heath & Pharma Biotechnology Award 2024 as Best Cancer Care Solutions Provider 2024 - UK
VasoDynamics Sets-up Laboratory at Stevenage Bioscience Catalyst
Laboratory facilities initiated to optimise development of product pipeline for the prevention of cancer therapy induced side-effects
